Hematology Department, Hospital Angeles Lomas, Huixquilucan, Estado de Mexico, Mexico.
Surgery Department, Hospital Angeles Lomas, Huixquilucan, Estado de Mexico, Mexico.
BMJ Case Rep. 2021 Nov 11;14(11):e243745. doi: 10.1136/bcr-2021-243745.
In the tyrosine kinase inhibitor era, the blast phase of chronic myeloid leukaemia (BP-CML) renders an uncommon presentation and has a poor prognosis with an estimated overall survival below 20%. Mixed-phenotype blast phase is even more infrequent, presenting in 3.3% of these patients. Blast phase manifests along haematological sarcomas, with extramedullary activity in lymph nodes, skin and bone. We report the case of a patient with an ovarian sarcoma as an extramedullary presentation of mixed-phenotype BP-CML refractory to conventional treatment which responded to immunotherapy against CD33 and CD19.
在酪氨酸激酶抑制剂时代，慢性髓性白血病的急变期（BP-CML）表现为一种不常见的表现，预后较差，总生存率估计低于 20%。混合表型急变期更为罕见，占这些患者的 3.3%。急变期表现为血液肉瘤，淋巴结、皮肤和骨骼有髓外活动。我们报告了一例卵巢肉瘤患者，其为混合表型 BP-CML 的髓外表现，对常规治疗难治，但对针对 CD33 和 CD19 的免疫治疗有反应。
